Ascendis Pharma (ASND) Misses Q3 EPS by 72c

Ascendis Pharma (NASDAQ: ASND) reported Q3 EPS of (EUR1.00), EUR0.72 worse than the analyst estimate of (EUR0.28). Revenue for the quarter came in at EUR213.63 million versus the consensus estimate of EUR213.17 million.

For earnings history and earnings-related data on Ascendis Pharma (ASND) click here.

You May Also Be Interested In

• Anthropic plans IPO potentially exceeding SpaceX's $86B record - Bloomberg
• Exchange Bank declares Q3 dividend, CEO to retire in 2027
• Bessent on Iran: maximum economic pressure means likely not a kinetic restart